Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in JAMA Oncol

Retrieve available abstracts of 74 articles:
HTML format



Single Articles


    January 2022
  1. ZHANG-VELTEN E, Iyengar P, Timmerman RD
    Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer-Does Size Matter?-Reply.
    JAMA Oncol. 2022 Jan 13. pii: 2788056. doi: 10.1001/jamaoncol.2021.7160.
    PubMed    


  2. OHRI N, Werner-Wasik M
    Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer-Does Size Matter?
    JAMA Oncol. 2022 Jan 13. pii: 2788057. doi: 10.1001/jamaoncol.2021.7157.
    PubMed    


  3. PU CY, Lusk CM, Neslund-Dudas C, Gadgeel S, et al
    Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
    JAMA Oncol. 2022 Jan 13. pii: 2788055. doi: 10.1001/jamaoncol.2021.6720.
    PubMed     Abstract available


  4. NITZ JA, Erkmen CP
    New 2021 USPSTF Lung Cancer Screening Criteria-An Opportunity to Mitigate Racial Disparity.
    JAMA Oncol. 2022 Jan 13. pii: 2788059. doi: 10.1001/jamaoncol.2021.6708.
    PubMed    


    November 2021
  5. POTTER AL, Yang CJ, Woolpert KM, Puttaraju T, et al
    Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines.
    JAMA Oncol. 2021 Nov 24. pii: 2786539. doi: 10.1001/jamaoncol.2021.5790.
    PubMed    


  6. KAPOOR A, Prabhash K
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Nov 4. pii: 2785696. doi: 10.1001/jamaoncol.2021.5608.
    PubMed    


  7. TIAN L, Huang B, Wei LJ
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Nov 4. pii: 2785697. doi: 10.1001/jamaoncol.2021.5605.
    PubMed    


  8. JABBOUR SK, Keller SM, Reck M
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2021 Nov 4. pii: 2785695. doi: 10.1001/jamaoncol.2021.5611.
    PubMed    


    October 2021
  9. SINGH H, Beaver JA, Pazdur R
    Immunotherapy for Patients With Small-Cell Lung Cancer-2 Gains, 2 Losses.
    JAMA Oncol. 2021 Oct 28. pii: 2785674. doi: 10.1001/jamaoncol.2021.4956.
    PubMed    


  10. MULSHINE JL, Pyenson B
    The Long, Slow Road to Lung Cancer Cure.
    JAMA Oncol. 2021 Oct 21. pii: 2784991. doi: 10.1001/jamaoncol.2021.4711.
    PubMed    


  11. GANTI AK, Klein AB, Cotarla I, Seal B, et al
    Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.
    JAMA Oncol. 2021 Oct 21. pii: 2784988. doi: 10.1001/jamaoncol.2021.4932.
    PubMed     Abstract available


  12. TOUMAZIS I, de Nijs K, Cao P, Bastani M, et al
    Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
    JAMA Oncol. 2021 Oct 21. pii: 2784987. doi: 10.1001/jamaoncol.2021.4942.
    PubMed     Abstract available


  13. ZHOU C, Ramalingam SS, Kim TM, Kim SW, et al
    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
    JAMA Oncol. 2021 Oct 14:e214761. doi: 10.1001/jamaoncol.2021.4761.
    PubMed     Abstract available


    September 2021
  14. DAGOGO-JACK I
    Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench.
    JAMA Oncol. 2021 Sep 2. pii: 2783495. doi: 10.1001/jamaoncol.2021.3369.
    PubMed    


  15. HORN L, Wang Z, Wu G, Poddubskaya E, et al
    Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2021 Sep 2. pii: 2783490. doi: 10.1001/jamaoncol.2021.3523.
    PubMed     Abstract available


    August 2021
  16. KHANDEKAR MJ, Keane FK
    Radiation Dose and Fractionation in Locally Advanced Lung Cancer: A Simple Question With a Complicated Answer.
    JAMA Oncol. 2021 Aug 12. pii: 2783009. doi: 10.1001/jamaoncol.2021.3180.
    PubMed    


  17. IYENGAR P, Zhang-Velten E, Court L, Westover K, et al
    Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.
    JAMA Oncol. 2021 Aug 12. pii: 2783004. doi: 10.1001/jamaoncol.2021.3186.
    PubMed     Abstract available


    July 2021
  18. EZE C, Belka C, Manapov F
    Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Jul 29. pii: 2782115. doi: 10.1001/jamaoncol.2021.2316.
    PubMed    


  19. TSAKIRIDIS T, Pond GR, Wright J, Ellis PM, et al
    Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 29. pii: 2782110. doi: 10.1001/jamaoncol.2021.2328.
    PubMed     Abstract available


  20. SKINNER H, Hu C, Tsakiridis T, Santana-Davila R, et al
    Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 29. pii: 2782111. doi: 10.1001/jamaoncol.2021.2318.
    PubMed     Abstract available


  21. GETTINGER SN, Redman MW, Bazhenova L, Hirsch FR, et al
    Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 15. pii: 2781889. doi: 10.1001/jamaoncol.2021.2209.
    PubMed     Abstract available


  22. BARTELS F, Wandrey MM, Aigner A, Stronisch T, et al
    Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer.
    JAMA Oncol. 2021 Jul 1. pii: 2781389. doi: 10.1001/jamaoncol.2021.2049.
    PubMed     Abstract available


  23. JACOBSON JO
    Accompanying Patients in the Time of COVID-19.
    JAMA Oncol. 2021;7:971-972.
    PubMed    


    June 2021
  24. HUI Z, Men Y, Hu C, Kang J, et al
    Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
    JAMA Oncol. 2021 Jun 24. pii: 2781087. doi: 10.1001/jamaoncol.2021.1910.
    PubMed     Abstract available


  25. JABBOUR SK, Lee KH, Frost N, Breder V, et al
    Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
    JAMA Oncol. 2021 Jun 4. pii: 2780855. doi: 10.1001/jamaoncol.2021.2301.
    PubMed     Abstract available


  26. TAKSLER GB, Peterse EFP, Willems I, Ten Haaf K, et al
    Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
    JAMA Oncol. 2021;7:885-894.
    PubMed     Abstract available


    May 2021
  27. CORBETT K, Sharma A, Pond GR, Brastianos PK, et al
    Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.
    JAMA Oncol. 2021 May 20. pii: 2780060. doi: 10.1001/jamaoncol.2021.1359.
    PubMed    


    April 2021
  28. SUN L, Tan M, Cohen RB, Langer CJ, et al
    Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.
    JAMA Oncol. 2021 Apr 15. pii: 2778198. doi: 10.1001/jamaoncol.2021.0546.
    PubMed    


  29. KAMRAN SC, Yeap BY, Ulysse CA, Cronin C, et al
    Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
    JAMA Oncol. 2021 Apr 8. pii: 2778095. doi: 10.1001/jamaoncol.2021.0281.
    PubMed     Abstract available


  30. WANG J, Lu S, Yu X, Hu Y, et al
    Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Apr 1. pii: 2777901. doi: 10.1001/jamaoncol.2021.0366.
    PubMed     Abstract available


  31. OSAROGIAGBON RU
    Tislelizumab-A Promising New Option for Enhancing Chemotherapy Benefit in Treatment for Advanced Squamous Cell Lung Cancer.
    JAMA Oncol. 2021 Apr 1. pii: 2777904. doi: 10.1001/jamaoncol.2021.0262.
    PubMed    


    March 2021
  32. ZENKE Y, Tsuboi M, Chiba Y, Tsujino K, et al
    Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Mar 18. pii: 2777344. doi: 10.1001/jamaoncol.2021.0113.
    PubMed     Abstract available


  33. ITO FUKUNAGA M, Wiener RS, Slatore CG
    The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening: The More Things Stay the Same....
    JAMA Oncol. 2021 Mar 9. pii: 2777056. doi: 10.1001/jamaoncol.2020.8376.
    PubMed    


    February 2021
  34. SINGH H, Pazdur R
    Contribution of Early Clinical Benefit End Points to Decreased Lung Cancer Mortality Rates.
    JAMA Oncol. 2021 Feb 25. pii: 2776763. doi: 10.1001/jamaoncol.2020.8090.
    PubMed    


  35. PATHAK R, Boffa DJ
    Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2021 Feb 25. pii: 2776759. doi: 10.1001/jamaoncol.2020.8194.
    PubMed    


  36. DAI J, Jin K, Jiang G
    Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Feb 25. pii: 2776757. doi: 10.1001/jamaoncol.2020.8186.
    PubMed    


  37. INAMURA K
    Adjuvant Chemotherapy in Patients With Early-Stage Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Feb 25. pii: 2776758. doi: 10.1001/jamaoncol.2020.8189.
    PubMed    


  38. PENNELL NA
    Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor-Mutant Lung Cancer.
    JAMA Oncol. 2021 Feb 4. pii: 2775934. doi: 10.1001/jamaoncol.2020.6755.
    PubMed    


  39. ASCHELE C, Negru ME, Pastorino A, Cavanna L, et al
    Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy.
    JAMA Oncol. 2021;7:304-306.
    PubMed    


  40. WANG Q, Berger NA, Xu R
    Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection.
    JAMA Oncol. 2021;7:220-227.
    PubMed     Abstract available


    January 2021
  41. AKAMATSU H, Toi Y, Hayashi H, Fujimoto D, et al
    Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomiz
    JAMA Oncol. 2021 Jan 7. pii: 2774521. doi: 10.1001/jamaoncol.2020.6758.
    PubMed     Abstract available


    December 2020
  42. ATKINS KM, Chaunzwa TL, Lamba N, Bitterman DS, et al
    Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Dec 17. pii: 2773837. doi: 10.1001/jamaoncol.2020.6332.
    PubMed     Abstract available


  43. SIEGEL DA, Fedewa SA, Henley SJ, Pollack LA, et al
    Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States.
    JAMA Oncol. 2020 Dec 3. pii: 2773380. doi: 10.1001/jamaoncol.2020.6362.
    PubMed    


  44. SCHOENFELD AJ, Yu HA
    Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply.
    JAMA Oncol. 2020;6:1983.
    PubMed    


  45. QI C, Cui H, Chen D
    Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers.
    JAMA Oncol. 2020;6:1982.
    PubMed    


    November 2020
  46. SIMONE CB 2ND
    Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases.
    JAMA Oncol. 2020 Nov 12. pii: 2772840. doi: 10.1001/jamaoncol.2020.5466.
    PubMed    


  47. RUSTHOVEN CG, Brown PD, Robin TP
    Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases-Reply.
    JAMA Oncol. 2020 Nov 12. pii: 2772841. doi: 10.1001/jamaoncol.2020.5473.
    PubMed    


    October 2020
  48. SHANKAR B, Zhang J, Naqash AR, Forde PM, et al
    Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Oct 29. pii: 2772169. doi: 10.1001/jamaoncol.2020.5012.
    PubMed     Abstract available


  49. ZHANG J, Fu J, Zhang G
    Assessing Expression of PD-L1 in Tumor-Associated Macrophages.
    JAMA Oncol. 2020;6:1634.
    PubMed    


  50. JABBOUR S, Simone CB 2nd, Malhotra J
    Assessing Expression of PD-L1 in Tumor-Associated Macrophages-Reply.
    JAMA Oncol. 2020;6:1634-1635.
    PubMed    


    September 2020
  51. BLAYNEY DW, Zhang Q, Feng J, Zhao Y, et al
    Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2020 Sep 24. pii: 2770700. doi: 10.1001/jamaoncol.2020.4429.
    PubMed     Abstract available


  52. ELKRIEF A, Kazandjian S, Bouganim N
    Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease 2019 Pandemic.
    JAMA Oncol. 2020 Sep 17. pii: 2770258. doi: 10.1001/jamaoncol.2020.4408.
    PubMed    


  53. PATHAK R, Goldberg SB, Canavan M, Herrin J, et al
    Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.
    JAMA Oncol. 2020 Sep 17. pii: 2770263. doi: 10.1001/jamaoncol.2020.4232.
    PubMed     Abstract available


    July 2020
  54. SANTANA-DAVILA R
    Hyperprogressive Disease After Treatment With Checkpoint Inhibitors: Time for Prospective Studies.
    JAMA Oncol. 2020;6:1046-1047.
    PubMed    


  55. YU HA, Schoenfeld AJ, Makhnin A, Kim R, et al
    Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
    JAMA Oncol. 2020;6:1048-1054.
    PubMed     Abstract available


  56. TAKVORIAN SU, Ladage VP, Wileyto EP, Mace DS, et al
    Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology.
    JAMA Oncol. 2020;6:1104-1106.
    PubMed    


    June 2020
  57. KAS B, Talbot H, Ferrara R, Richard C, et al
    Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 11. pii: 2766806. doi: 10.1001/jamaoncol.2020.1634.
    PubMed     Abstract available


  58. LE PECHOUX C, Levy A
    Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases: A Call for Prospective Evidence.
    JAMA Oncol. 2020 Jun 4. pii: 2766562. doi: 10.1001/jamaoncol.2020.1245.
    PubMed    


  59. RUSTHOVEN CG, Yamamoto M, Bernhardt D, Smith DE, et al
    Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.
    JAMA Oncol. 2020 Jun 4. pii: 2766565. doi: 10.1001/jamaoncol.2020.1271.
    PubMed     Abstract available


  60. BERCHUCK JE, Meyer CS, Zhang N, Berchuck CM, et al
    Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 4. pii: 2766567. doi: 10.1001/jamaoncol.2020.1466.
    PubMed     Abstract available


    May 2020
  61. MIYAMOTO S, Azuma K, Ishii H, Bessho A, et al
    Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    JAMA Oncol. 2020 May 14:e201250. doi: 10.1001/jamaoncol.2020.1250.
    PubMed     Abstract available


  62. LIU Y, Colditz GA, Kozower BD, James A, et al
    Association of Medicaid Expansion Under the Patient Protection and Affordable Care Act With Non-Small Cell Lung Cancer Survival.
    JAMA Oncol. 2020 May 14. pii: 2765753. doi: 10.1001/jamaoncol.2020.1040.
    PubMed    


    April 2020
  63. SANCHEZ A, Furberg H
    Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy.
    JAMA Oncol. 2020 Apr 23. pii: 2764900. doi: 10.1001/jamaoncol.2020.0634.
    PubMed    


  64. KICHENADASSE G, Hopkins AM, Sorich MJ
    Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy-Reply.
    JAMA Oncol. 2020 Apr 23. pii: 2764902. doi: 10.1001/jamaoncol.2020.0643.
    PubMed    


  65. RIZVI NA, Cho BC, Reinmuth N, Lee KH, et al
    Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2020 Apr 9. pii: 2763864. doi: 10.1001/jamaoncol.2020.0237.
    PubMed     Abstract available


  66. WAQAR SN, Govindan R
    The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy.
    JAMA Oncol. 2020 Apr 9. pii: 2763860. doi: 10.1001/jamaoncol.2020.0264.
    PubMed    


  67. ARRIETA O, Barron F, Ramirez-Tirado LA, Zatarain-Barron ZL, et al
    Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2020 Apr 9. pii: 2763865. doi: 10.1001/jamaoncol.2020.0409.
    PubMed     Abstract available


  68. LION AH
    First Rites-A Spiritual History Case Study.
    JAMA Oncol. 2020;6:475-476.
    PubMed    


    March 2020
  69. TERUYA H, Mukaigawara M, Hirata K
    Progressive Dyspnea in a Woman With Genital Skin Lesions.
    JAMA Oncol. 2020;6:433-434.
    PubMed    


  70. ROUSSEAU P
    One Patient's Perspective on Terminal Cancer-Sometimes It Is Best Not to See.
    JAMA Oncol. 2020;6:329.
    PubMed    


    February 2020
  71. LU S, Wang H, Taube JM
    Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies-Reply.
    JAMA Oncol. 2020;6:299.
    PubMed    


  72. KAZANDJIAN D, Gong Y, Blumenthal GM
    Application of the Lung Immune Prognostic Index From Research to Clinical Practice-Reply.
    JAMA Oncol. 2020;6:300-301.
    PubMed    


  73. LONG J, Lin J, Zhao H
    Application of the Lung Immune Prognostic Index From Research to Clinical Practice.
    JAMA Oncol. 2020;6:299-300.
    PubMed    


  74. LIU S, Niu W
    Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies.
    JAMA Oncol. 2020;6:298-299.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: